Literature DB >> 34600604

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.

Ildiko Lingvay1, Priya Sumithran2, Ricardo V Cohen3, Carel W le Roux4.   

Abstract

Obesity is now recognised as a disease that is associated with serious morbidity and increased mortality. One of its main metabolic complications is type 2 diabetes, as the two conditions share key pathophysiological mechanisms. Weight loss is known to reverse the underlying metabolic abnormalities of type 2 diabetes and, as such, improve glucose control; loss of 15% or more of bodyweight can have a disease-modifying effect in people with type 2 diabetes, an outcome that is not attainable by any other glucose-lowering intervention. Furthermore, weight loss in this population exerts benefits that extend beyond glycaemic control to improve risk factors for cardiometabolic disease and quality of life. We review the evidence supporting the role of weight loss in the management of type 2 diabetes and propose that many patients with type 2 diabetes would benefit from having a primary weight-centric approach to diabetes treatment. We discuss the logistical challenges to implementing a new weight-centric primary treatment goal in people with type 2 diabetes.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34600604     DOI: 10.1016/S0140-6736(21)01919-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

Review 2.  Precision nutrition in diabetes: when population-based dietary advice gets personal.

Authors:  Jordi Merino
Journal:  Diabetologia       Date:  2022-05-20       Impact factor: 10.460

Review 3.  The Adipose Tissue Macrophages Central to Adaptive Thermoregulation.

Authors:  Md Shamim Rahman; Heejin Jun
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

4.  Diabetes Fact Sheet in Korea 2021.

Authors:  Jae Hyun Bae; Kyung-Do Han; Seung-Hyun Ko; Ye Seul Yang; Jong Han Choi; Kyung Mook Choi; Hyuk-Sang Kwon; Kyu Chang Won
Journal:  Diabetes Metab J       Date:  2022-05-25       Impact factor: 5.893

5.  Revisiting the strategies for the pharmacological management of type 2 diabetes - From glycemic control, organ protection, safety to weight reduction.

Authors:  Hung-Yuan Li
Journal:  J Diabetes Investig       Date:  2021-12-14       Impact factor: 4.232

Review 6.  Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases.

Authors:  Chao-Yue Sun; Zuo-Liang Zheng; Cun-Wu Chen; Bao-Wei Lu; Dong Liu
Journal:  Front Microbiol       Date:  2022-03-15       Impact factor: 5.640

Review 7.  Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?

Authors:  Matthias Blüher; Antonio Ceriello; Melanie Davies; Helena Rodbard; Naveed Sattar; Oliver Schnell; Elena Tonchevska; Francesco Giorgino
Journal:  Endocrinol Diabetes Metab       Date:  2022-03-17

8.  MiR-203 is an anti-obese microRNA by targeting apical sodium-dependent bile acid transporter.

Authors:  Xin Liu; Feiran Cheng; Xue Bai; Tong Zhao; Limin Zhao; Lei Wang; Mingqi Li; Xianxian Wu; Xiaohui Chen; Pingping Tang; Mengxue Wang; Lintong Jiang; Chaoqi Yan; Fenghua Pei; Xu Gao; Ning Ma; Baofeng Yang; Yong Zhang
Journal:  iScience       Date:  2022-07-02

Review 9.  Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?

Authors:  Ides M Colin; Katherine M Gérard
Journal:  touchREV Endocrinol       Date:  2022-06-15

Review 10.  INDY as a Therapeutic Target for Cardio-Metabolic Disease.

Authors:  Dominik Pesta; Jens Jordan
Journal:  Metabolites       Date:  2022-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.